by Sarah Charles for Age of Coffee

The food and beverage industry is constantly thinking up new ways to make us eat and drink more. Now it is spending billions to serve a growing cohort of consumers who, for the first time, genuinely cannot.

GLP-1 medications like Ozempic, Wegovy, and Mounjaro have created a new consumer category so significant that Starbucks is rebuilding its menu around it, McDonald’s has announced an $8.5 billion overhaul partly in response to it, and Nestle and Unilever are launching dedicated product lines to serve it. The market research firms call them super consumers. The National Coffee Association (NCA)’s Fall 2026 NCDT report puts their number at 54.7 million Americans – that’s roughly 16% of the adult population – currently using or having used GLP-1 medications. That the NCA is reporting on weight-loss drug users at all speaks for itself. This structural shift is arriving at exactly the moment when coffee consumption in the U.S is already at its lowest per capita level since 2003.

The super consumer is, according to surveys, a specific market: a married, urban Gen X or Millennial with children at home, earning over $100,000 in annual household income. A demographic that is more than twice as likely to be in that income bracket as the general adult population. 27% hold a master’s degree or above, versus 12% of all adults. These are peak-earning, high-spending consumers that brands cannot afford to ignore. This reported estimate, if true, is a case in point:

“9% of adults drive 34% of candy consumption. Assume that one-third of those adults successfully adopt Ozempic or another GLP-1, and that’s a roughly 10% hit to category sales.”

What GLP-1 does to consumption

Kate Moss once said that nothing tastes as good as skinny feels. It was aspirational in a way that made eating seem like a moral failure. Fast-forward roughly fifteen years, and it is almost as if someone turned that phrase into a medication.

GLP-1 drugs suppress appetite by doing something more fundamental than reducing hunger: they remove the pleasure of eating and drinking entirely.

IFF, the flavor and fragrance company, has been conducting ongoing research into the food preferences of GLP-1 users and found that the medications “commonly disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel.” Among the most frequently rejected foods are fatty dishes, deli meats, sweets, and coffee. Professor Jens Juul Holst of the University of Copenhagen, one of the scientists who pioneered GLP-1 research, put it plainly in an interview with Wired: “What happens is that you lose your appetite and also the pleasure of eating. Once you’ve been on this for a year or two, life is so miserably boring that you can’t stand it any longer.”

GLP-1 drugs also slow gastric emptying, which means food and drink, including caffeine, stay in the stomach longer, worsening side effects like nausea, acid reflux, and stomach irritation. Fox News and the New York Post have both reported that caffeinated beverages can interfere with oral GLP-1 medications, which must be taken on an empty stomach. Doctors advise users to wait at least 30 minutes before drinking coffee. A Reddit thread on the subject captures what the statistics compress: “The dopamine for that first cup isn’t like it used to be. I want the coffee, so I make it, but that first sip isn’t the same.”

For coffee specifically, the data from the NCA is striking.

Among GLP-1 users, 36% (nearly 20 million people) report they are likely to drink less coffee. The economic impact is already measurable.

Cornell University research found that within six months of starting a GLP-1 medication, households reduce grocery spending by an average of 5.3%. Among higher-income households, the drop exceeds 8%. Spending at fast-food restaurants and coffee shops falls by approximately 8%. Applied across 54.7 million users, these shifts represent a structural change in consumer behaviour that the food and beverage industry is only beginning to reckon with.

The race to capture the GLP-1 consumer

Starbucks CEO Brian Niccol has been explicit about the GLP-1 pivot: ‘What I’ve noticed, as I’ve understood the behaviors associated with people that ultimately are on GLP-1s, is you end up with more snacking or smaller meals, and more protein forward, more fiber forward,” he told Yahoo Finance. The controversial CEO reduced the Starbucks menu by roughly 25-30% when he joined the company, and is now adding protein balls, flatbreads, wraps, baked goods, sugar-free syrups, protein milk, and protein cold foam. He is also betting on the afternoon as a new consumption occasion, “a multibillion-dollar opportunity,” partly to compensate for morning traffic lost to GLP-1 side effects.

McDonald’s has gone further still. At its Investor Day presentation in Chicago on September 23, executives announced an $8.5 billion overhaul over the next decade, with GLP-1 users a stated driver. New wraps, grilled chicken sandwiches, bowls, and egg bites are planned across markets. “This is an opportunity. We need to keep giving them more reasons to make McDonald’s their first choice,” said Skye Anderson, president of McDonald’s USA.

The scale of the coming shift is huge. In 2025, US households with at least one GLP-1 user grew to 20% from 9% the previous year.

The average household with a GLP-1 user spends 4-6% less on food and grocery goods, making competition for that wallet steeper across the board. Novo Nordisk’s Wegovy pill, introduced in January 2026, saw more than 18,000 prescriptions in its first week.

Morgan Stanley notes that energy drinks are gaining share within caffeinated beverages, partly driven by GLP-1 users who need caffeine but find coffee harder to tolerate, replacing not just coffee but alcohol and snacks as an “affordable indulgence.” Among recent switchers from coffee to energy drinks, 57% cited more caffeine per beverage and 45% pointed to convenience.

The coffee industry’s response has been more tentative. Some cafés are expanding herbal tea and low-acid offerings to retain GLP-1 users who can no longer tolerate a standard espresso. The NCA data offers a small consolation: current GLP-1 users report higher past-day specialty coffee consumption than the general population, suggesting that those who still drink coffee are gravitating toward quality over quantity. That is an opening for specialty, if the sector chooses to take it seriously.

The less comfortable story

There is, however, a dimension to this that deserves more scrutiny than it is currently receiving. The companies most aggressively pivoting to serve GLP-1 users are, in many cases, the same companies whose products contributed to the health conditions that GLP-1 medications are designed to treat.

Those who created the problem – obesity and health problems – are also manufacturing the solution – weight loss drugs and supplements – and cashing in.

Multinationals with vast ranges of ultra-processed products, are launching dedicated lines positioned as ideal for GLP-1 users. Some are even developing their own weight-loss supplements. These companies are simultaneously marketing existing products as high-protein alternatives for GLP-1 users, while continuing to produce the ultra-processed foods that are among the most frequently rejected by people on those same medications.

The pattern extends to beauty and skincare, where brands have launched GLP-1-specific product lines addressing the medication’s side effects – hair loss, fatigue, skin changes – creating an entirely new commercial category around managing the consequences of a drug that manages the consequences of, in part, decades of ultra-processed food consumption. Lars Fruergaard Jørgensen, CEO of Novo Nordisk, the maker of Ozempic and Wegovy, reportedly told Bloomberg that food company executives have been calling him for advice, scared about what is coming.

What this means for coffee

For the coffee industry, the GLP-1 moment is a threat that many are attempting to spin into a narrowly defined opportunity. The threat is straightforward: 20 million American GLP-1 users likely to reduce coffee consumption, combined with an 8% decline in coffee shop traffic from this cohort. Add the broader per capita consumption decline already underway, and you have cause for concern.

The opportunity is specific. GLP-1 users who continue to drink coffee skew toward specialty.

They are affluent, health-conscious, and responsive to premium positioning. They are also, per surveys, digitally omnipresent and early adopters. A coffee industry that can offer lower-acid options, protein-enhanced formats, and genuine nutritional transparency – or even sweet, customizable, frozen blended coffee drinks – is well placed to retain this cohort even as the broader population shifts.

The question is whether the industry moves toward that opportunity deliberately, or simply watches energy drinks fill the gap.